Century Therapeutics Inc (IPSC)vsBeiGene, Ltd. (ONC)
IPSC
Century Therapeutics Inc
$2.24
-5.49%
HEALTHCARE · Cap: $434.93M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 4795% more annual revenue ($5.34B vs $109.16M). ONC leads profitability with a 5.4% profit margin vs -8.8%. ONC earns a higher WallStSmart Score of 42/100 (D).
IPSC
Avoid27
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IPSC.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -6.0% — below average capital efficiency
Revenue declined 100.0%
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : IPSC
The strongest argument for IPSC centers on Price/Book.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : IPSC
The primary concerns for IPSC are EPS Growth, Market Cap, Return on Equity.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
IPSC profiles as a turnaround stock while ONC is a hypergrowth play — different risk/reward profiles.
IPSC carries more volatility with a beta of 1.72 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 27/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Century Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Century Therapeutics Inc. (Ticker: IPSC) is a pioneering biotechnology company dedicated to advancing allogenic cell therapies that aim to revolutionize cancer treatment. Leveraging its proprietary induced pluripotent stem cell (iPSC) technology, the company is developing innovative off-the-shelf therapeutic solutions designed to improve both patient outcomes and accessibility. With a strong pipeline of clinical-stage product candidates and strategic collaborations enhancing its competitive advantage, Century Therapeutics is well-positioned to drive innovation in the rapidly expanding cell therapy landscape, presenting compelling potential for clinical breakthroughs and favorable shareholder returns.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?